CALADRIUS BIOSCIENCES, INC. (NASDAQ:CLBS) Files An 8-K Other Events
Item 8.01 Other Events
issued a press release in connection with the previously
announced private placement in September 2016. A copy of the
press release is furnished as Exhibit 99.1 to this Current Report
on Form 8-K (the “Current Report”) and is incorporated into this
Item 8.01 by reference.
|
Exhibit No.
|
Description
|
|
99.1
|
Press Release, dated January 6, 2017
|
About CALADRIUS BIOSCIENCES, INC. (NASDAQ:CLBS)
Caladrius Biosciences, Inc., formerly NeoStem, Inc., through its subsidiary, PCT, LLC, a Caladrius Company (PCT), provides development and manufacturing services to the cell therapy industry (which includes cell-based gene therapy). PCT specializes in cell and cell-based gene therapies. PCT offers development and manufacturing capabilities, quality systems, cell and tissue processing, logistics, storage and distribution and engineering solutions to clients with therapeutic candidates at all stages of development. The Company’s product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient’s own numerically and functionally enhanced Tregs. This therapy is based on a platform technology for immunomodulation. The Company’s T Regulatory Cell Technology is applicable to multiple autoimmune and allergic diseases. CALADRIUS BIOSCIENCES, INC. (NASDAQ:CLBS) Recent Trading Information
CALADRIUS BIOSCIENCES, INC. (NASDAQ:CLBS) closed its last trading session down -0.05 at 3.28 with 66,602 shares trading hands.
